Digital PCR Market Forecasts from 2023 to 2028

The digital PCR market is anticipated to reach a market size of US$12.456 billion in 2028.

The digital PCR market is anticipated to rise at a steady pace during the projected period. A development over classical PCR, digital PCR is used to measure and identify DNA or a specific portion of the DNA molecule. It distributes a DNA sample or complementary DNA sample to numerous people, through parallel PCR processes. Applications for it include DNA cloning, hereditary illness diagnosis, functional gene analysis, paternity testing, infectious disease detection, and forensic sciences.

Growth drivers for the digital PCR market

A significant element driving the digital PCR market of the worldwide digital polymerase chain reaction market is the rise in the prevalence of many malignancies, including blood cancer, lung cancer, and brain tumors. A digital PCR test is utilized for cancer molecular diagnostics. The benefits of digital PCR over traditional PCR technologies, such as RT-PCR and quantitative polymerase chain reaction (qPCR), are also anticipated to increase their utilization throughout the projection period. The digital PCR market is expanding because of rising healthcare expenditures for people in developing countries as well as a rise in demand for accurate genetic disease identification.

The droplet digital PCR segment is anticipated to dominate the market

Droplet digital PCR (ddPCR), a technique for carrying out digital PCR, is based on the droplet technology of a water-oil emulsion. A sample is divided into 20,000 droplets, and each droplet undergoes PCR amplification of the template molecules. The chemicals and procedures utilized by the ddPCR method are comparable to those of the majority of common TaqMan probe-based tests. A crucial component of the ddPCR process is the large sample splitting. In addition to the benefits of the ddPCR already mentioned, factors driving the digital PCR market include the rising incidence of infectious illnesses and cancer, as well as increased financing for breakthroughs in the biotechnology industry.

The development of droplet digital PCR is mostly driven by advancements in technology and rising consumer demand. Absolute quantification, for instance, is offered by the QX200 Droplet Digital PCR System from BioRAD.

Technological advancements

The development of droplet digital PCR is mostly driven by advancements in technology and rising consumer demand. For instance, the QX200 Droplet Digital PCR System from BioRAD allows for the digital absolute quantification of target DNA. These products evaluate the degree of gene expression with unmatched precision, detect uncommon DNA target copies, and assess copy number variation.

Additionally, businesses are introducing goods related to droplet technology. The Droplet Digital PCR SARS-CoV-2 Test Kit was granted emergency use authorization by the US Food and Drug Administration (FDA) in May 2020.

Clinical diagnostics is anticipated to show a high prevalence

This can be attributed to several things, including the rising incidence of diseases like cancer, infectious diseases, and diabetes; high testing precision; increased commercialization of diagnostic reagents; effective disease diagnosis, monitoring, and treatment; and additional advantages in disease detection and is driving the digital PCR market. For instance, Thermo Fisher Scientific Inc. unveiled The QuantStudio 6 & 7 Pro RT-PCR Systems. These systems have extra capabilities including facial recognition, voice assistant, and RF identification. Similar to this, Thermo Fisher Scientific's QuantStudio Dx family of equipment will begin receiving 37 CE-IVD-marked real-time PCR test kits for various infectious illnesses.

North America is anticipated to dominate the digital PCR market

Throughout the whole projection period, North America is anticipated to lead the digital PCR market as a whole. The existence of major companies, the high frequency of chronic illnesses in the area, and the developed healthcare infrastructure all contribute to the market's growth. In addition, encouraging government efforts and a rise in research collaboration numbers are among the factors anticipated to boost digital PCR market growth. Due to its pro-healthcare legislation, large patient population, and established healthcare sector, the United States has the largest share in this area. According to the American Cancer Society's 2021 report, there were about 1,898,160 cancer diagnoses in 2021, including 970,250 men and 927,910 women in the United States as well as 608,570 cancer-related deaths.

The growing trend of genetic engineering and genomic research

Genetic engineering and genomic research are on the rise in American academia and the biotechnology sector. Additionally, the increased need for focused and precise medicine for the treatment of chronic illnesses and the requirement to comprehend the genetic and molecular causes of disease are the main drivers of growing genomic research.

These kinds of initiatives are creating an atmosphere that is conducive to the development and commercialization of gene-based diagnostics and therapies by pharmaceutical and biotechnology companies. Due to its numerous uses in drug development, toxicity and effectiveness investigations, as well as in general life science research, digital PCR technologies are expected to increase as a result and will drive the digital PCR market growth.

The presence of sophisticated diagnostic laboratories

The digital PCR market growth can be ascribed to the availability of highly developed diagnostic facilities and the high rate of acceptance of innovative test methods. Genetic engineering and genomic research are on the rise in American academia and the biotechnology sector. These kinds of initiatives are creating an atmosphere that is conducive to the development and commercialization of gene-based diagnostics and therapies by pharmaceutical and biotechnology companies. This is driving the United States digital PCR market.

Market Key Developments

• In February 2023, A portable RT-PCR device created by Huwel Lifesciences may be used to evaluate various viral kinds.
• In April 2023, to specifically target the XBB, F. Hoffmann-La Roche Ltd. created the innovative COVID-19 PCR test VirSNiP SARS-CoV-2 Spike F486P.
• In February 2022, The COVID-19 PCR tests were expanded by F. Hoffmann-La Roche Ltd. in nations that accepted the CE market.

Segmentation:

By Technology

• Droplet Digitial PCR
• Chip Based Digital PCR
• Beaming Digital PCR

By Product Type

• Digital PCR Systems
• Consumables and Reagents
• Software and Services

By Application

• Clinical Diagnostics
• Forensic and Others
• Research

By End-User

• Pharmaceuticals and Biotechnology Industries
• Clinical Diagnostic Laboratories
• Universities and Other Organizations

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others